A new machine learning tool called GLUCOSE helps doctors manage blood sugar levels in patients recovering from heart surgery by recommending tailored insulin doses. The model outperformed experienced clinicians in keeping blood sugar levels within a safe range, despite using only current patient data.
Researchers will present AI models that predict chronic respiratory failure and detect airway obstruction, with key findings on asthma susceptibility, small airway disease, and lung inflammation. The studies use nasal epithelial gene expression analyses and bronchoscopy to identify potential biomarkers for ICU patient outcomes.
Researchers have identified a mechanism involving potassium channels that could provide a new approach to treating depression. The study, led by Dr. James Murrough, found that ezogabine improved depression symptoms and anhedonia in patients, normalizing brain activity in key regions.
Surgeons at Mount Sinai performed the world's first heart-liver-kidney triple organ transplants in New York State, with two patients making full recoveries after the surgeries. The procedures were led by Anelechi Anyanwu and Sander S. Florman and represent a significant milestone in complex organ transplantation.
Research found that women whose sister experienced postpartum psychosis are over 10 times more likely to experience it themselves. The study highlights genetic and shared environmental influences and suggests early recognition and prevention are crucial.
Dr. Miriam Merad has been recognized for her groundbreaking research on macrophage biology and immunology, with a focus on cancer and chronic inflammatory disease. Her work has led to the development of novel therapeutic targets and has improved treatment outcomes for patients with lung cancer.
Researchers will discuss increasing the use of low-dose aspirin for preeclampsia prevention through universal implementation. Additionally, experts will present on the impact of doula care on social determinants of health, exploring its potential to address non-medical healthcare disparities within the system.
A study published in Brain found that the orbitofrontal cortex responds more strongly to drug content than other stimuli, even after treatment and abstinence. The researchers used an Academy Award-nominated movie to assess brain responses in individuals with heroin use disorder and healthy controls.
Dr. Charney will retire at the end of his current term on June 30; Eric J. Nestler, MD, PhD, appointed interim dean. Under his leadership, the Icahn School of Medicine advanced its reputation as an international leader in biomedical education and research.
The Mount Sinai team's NYC-Vita trial combines lifestyle and pharmaceutical interventions to rebalance the immune system and restore health in older adults. The ambitious effort aims to develop practical, science-driven interventions that extend life and restore energy, focus, and strength.
Researchers discovered distinct roles for dopamine receptors in the ventral hippocampus, a region involved in emotions and stress responses. The study highlights the importance of dopamine signaling in anxiety and mood disorders.
A novel AI model developed by researchers at Mount Sinai improved delirium detection by quadrupling the rate of identification and treatment in hospitalized patients. The model accurately calculates delirium risk in real-time and integrates smoothly into clinical workflows, helping staff catch and treat more patients with delirium.
Researchers found persistent inflammation in heart and lungs of patients with long COVID, even after standard tests return normal results. This study uses advanced PET/MRI imaging to detect abnormal patterns that could serve as early warning signs of future cardiac and pulmonary conditions.
Eric J. Nestler, a world-leading expert on addiction and depression, has been elected to the National Academy of Sciences (NAS) for his distinguished achievements in original research. The recognition is a testament to his extensive scientific experience and impact on the field of neuroscience.
The Icahn School of Medicine at Mount Sinai is providing all medical and graduate students with access to OpenAI's ChatGPT Edu private and secure platform. This move enhances its educational toolkit, equipping students with cutting-edge AI solutions to succeed in the rapidly evolving healthcare ecosystem.
Researchers identified how the brain assigns positivity or negativity to social experiences through a complex neural circuitry involving the hippocampus. They discovered that serotonin and neurotensin release opposing signals in the ventral CA1 region, which can be leveraged for future therapies.
A new AI algorithm, Viz HCM, can quickly and specifically identify high-risk heart patients with hypertrophic cardiomyopathy (HCM) and provide individualized risk assessments. The algorithm's findings can help doctors prioritize the highest-risk patients for earlier appointments and treatment.
A new AI algorithm has been calibrated to quickly identify patients with hypertrophic cardiomyopathy (HCM) and provide individualized risk assessments. The tool can help prioritize high-risk patients for earlier appointments and treatment, leading to better patient outcomes.
The Mount Sinai Fuster Heart Hospital cardiology faculty practice has received the 2024 Human Experience Pinnacle of Excellence Award from Press Ganey, a leading patient experience organization. The hospital ranks among the top 5% of healthcare providers in delivering patient experience over three years.
Using intravascular imaging (IVI) to guide stent implantation reduces death, stent thrombosis, and repeat procedures in severely calcified lesions. IVI outperforms conventional angiography in improving patient outcomes.
A new study reveals that inherited germline genetic variants significantly influence the biology of tumors, altering protein activity, gene expression, and tumor interactions with the immune system. The research suggests that considering a patient's inherited DNA could refine diagnosis, risk prediction, and therapy selection.
Researchers at Mount Sinai School of Medicine have identified a new genetic cause of neurodevelopmental disorders (NDDs), including mutations in the previously overlooked non-coding gene RNU2-2. The discovery offers hope to potentially thousands of families worldwide, providing closure and support for those affected by these conditions.
A study by researchers at Mount Sinai reveals that generative AI models may recommend different treatments for the same condition based solely on a patient's demographic background. The study highlights the need for early detection and intervention to ensure safe, effective, and appropriate care.
The Playbook Workflow Builder simplifies data analysis and streamlines collaboration for biomedical researchers. Researchers can design custom workflows using pre-built analytical components, removing a major barrier to data-driven discovery.
The Mount Sinai Hospital has launched an AI Small Molecule Drug Discovery Center to revolutionize the creation of life-saving medicines. The center will use cutting-edge AI to design and optimize novel therapeutics with unprecedented speed and precision.
Dr. Brian Brown is recognized for his groundbreaking work in gene therapy and functional genomics, which has helped transform the fields and contributed to key advancements in medicine and biotechnology. His innovations have been broadly used across biomedical fields, including cancer, immunology, and genetic disease research.
The national healthcare initiative has been extended for five years to provide world-class healthcare services to every Guyanese citizen. The partnership will establish a national cancer center, modernize national health facilities, and implement an advanced digital health system.
The Mount Sinai Hospital has launched a new center focused on advancing artificial intelligence (AI) driven outcomes in children's health. The center aims to improve diagnostics, personalize treatments and optimize healthcare delivery for youth and adolescents. Dr. Benjamin S. Glicksberg will lead the Center.
A Mount Sinai-led team has discovered a link between gamma delta intraepithelial lymphocytes and the development of Crohn's disease. By analyzing a mouse model, they found that impaired communication between these cells led to inflammation in the lower small intestine.
Researchers developed a new therapy that teaches patients to tolerate stomach and body discomfort, improving functional brain deficits linked to visceral disgust. The study showed improved outcomes for adolescents with low-weight eating disorders compared to traditional family-based treatment.
A powerful AI tool, PFTSleep, has been developed to process an entire night's sleep with high accuracy. The model, built on transformer architecture, analyzes brain waves, muscle activity, heart rate, and breathing patterns to classify sleep stages more effectively than traditional methods.
Researchers identified nine distinct types of T cells that harbor inactive HIV cells, and persistent T cells with HIV even after antiretroviral therapies. This discovery brings medical experts closer to a cure for the infection affecting nearly 40 million people globally.
Mount Sinai Hospital has been ranked the top hospital in New York State for three consecutive years by Newsweek/Statista. The hospital has also seen significant improvements in rankings within the US and globally, moving up to No. 7 in the country and No. 19 worldwide.
New York City residents can now access behavioral health treatment services, including cognitive therapy and medication management, at Mount Sinai's Center for Stress, Resilience and Personal Growth. The center aims to help individuals strengthen resilience, improve well-being, and navigate life challenges with confidence.
The Mount Sinai Hospital has become the first in the US to perform a deep brain stimulation (DBS) implantation procedure as part of a clinical trial investigating its effectiveness for treatment-resistant depression. The study aims to gather evidence on the impact of DBS systems developed by healthcare company Abbott.
Researchers have discovered a novel approach to protecting insulin-producing beta cells from glucolipotoxicity, a condition linked to type 2 diabetes progression. The findings could lead to promising treatments targeting beta cell dysfunction, potentially slowing or preventing disease progression.
The Mount Sinai Parenting Center will expand its marquee programs to educate healthcare providers on social, emotional, and cognitive development during early childhood. The $2.2 million grant will support the training of an additional 30,000 primary care providers through the Keystones of Development Provider Portal.
A new study found that physical activity can significantly improve mental well-being in women with chronic pelvic pain disorders, such as endometriosis and uterine fibroids. The benefits appear to accumulate over time, highlighting the importance of consistency in physical activity.
A Mount Sinai-led research team has identified stem cell populations and mechanisms underlying age-related degeneration in meibomian glands, which secrete lipid-rich meibum to prevent tear evaporation. The findings suggest that targeting Hh and EGFR signaling could be a potential therapeutic option for evaporative dry eye disease.
Researchers at Mount Sinai developed iDOMO, a computational tool that predicts effective drug pairings using gene expression data. The study successfully identified a promising combination for triple-negative breast cancer, validating its prediction.
Researchers at The Mount Sinai Hospital have identified 10 novel gene pairs potentially linked to the development of CHD. Their study uses trio exome sequencing data to uncover previously hidden genetic risks, which could improve diagnostic precision and open new avenues for personalized treatment strategies.
A study published in Mayo Clinic Proceedings found that patients who can exercise during cardiac stress testing have a lower mortality rate than those who cannot. The researchers discovered that assessing a patient's ability to exercise during testing provides a stronger distinction between high- and low-risk patients.
A new study published in Nature Materials demonstrates a lipid nanoparticle system capable of delivering messenger RNA to the brain via intravenous injection. The technology could pave the way for future treatments for conditions like Alzheimer's disease and drug addiction.
A new medication approved to treat type 2 diabetes and kidney disease also significantly reduces the risk of heart attacks and strokes among these patients. Sotagliflozin, a sodium-glucose cotransporter inhibitor, blocks proteins that help control blood sugar levels and has been shown to reduce cardiovascular events by 23%.
Researchers identified the cortical amygdala as a key brain region in promoting aggression, but inhibiting this area reduces aggressive behavior and induces pro-social behavior. The study found that cells in the cortical amygdala respond to male social stimuli, enhancing attack behavior.
Researchers found that olpasiran significantly lowers lipoprotein(a) levels by over 95% and reduces oxidized phospholipids, which promote atherosclerosis. The study also showed no significant effects on inflammatory markers.
A new study led by researchers at Mount Sinai Hospital found that children with high-threshold peanut allergy can be treated with a safe and effective approach, allowing them to tolerate larger doses of peanut butter. The treatment involves gradually increasing doses over 18 months, resulting in sustained unresponsiveness to peanuts fo...
Researchers used intracranial EEG recordings to find that meditation led to changes in the amygdala and hippocampus, key regions involved in emotional regulation and memory. Loving kindness meditation was specifically found to be associated with changes in brain wave activity.
Researchers from The Mount Sinai Hospital analyzed an AI system to detect heart defects on fetal ultrasound exams, finding it significantly improved detection rates. The study aimed to improve prenatal detection of congenital heart defects, a leading cause of infant morbidity and mortality.
Dr. Girish N. Nadkarni, a pioneering physician-scientist, has been named Chair of the Windreich Department of Artificial Intelligence and Human Health and Director of the Hasso Plattner Institute for Digital Health at Mount Sinai. He will lead efforts to advance AI research, education, and clinical translation.